CytomX Therapeutics
Most recent annual filing: 2026-03-15
- Varseta-M trial start2H 2026Varseta-M trial start, 2H 2026, notable
- CX-801 Ph1 readoutLate 2026CX-801 Ph1 readout, Late 2026, material
- CX-801 readoutEnd of 2026CX-801 readout, End of 2026, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
CX-801
Protein Target: IFNα2b, interferon alpha-2b
CX-908
Protein Target: CDH3, P-Cadherin, CD3
- Undisclosed indication
Varseta-M
varsetatug masetecanTechnology platforms
PROBODY
Conditionally activated, masked biologics platform leveraging tumor-associated proteases to selectively activate biologic therapeutics in the tumor microenvironment; applied across ADCs, T-cell engagers, cytokines, and mRNA modalities for oncology
PROBODY · Regeneron
Biologic masking platform that produces conditionally activated, masked antibody-based therapeutics localized to the tumor microenvironment via protease activation; used for ADCs, cytokines, T-cell engagers, and bispecific antibodies in oncology
Discontinued (2)
- praluzatamab ravtansine — Breast Cancer · Phase 2 did not show required progression free survival; program deprioritized; CX-2009 License terminated in 2025
- CX-904 — undisclosed · jointly discontinued the program in March 2025
Biotech Distilled coverage (5)
- 2026-08-07 UPDATE: CytomX Therapeutics (CTMX) - Two Partners Walked, One Doubled Down 🔒 Paid
- 2026-06-03 UPDATE: CytomX Therapeutics (CTMX) - Regeneron Doubles Down on the Mask
- 2026-04-18 UPDATE: CytomX Therapeutics (CTMX) - Act III of the Institutional Drama 🔒 Paid
- 2026-03-22 UPDATE: CytomX (CTMX) - Clears the Binary Hurdle and Executes the Classic Biotech Playbook 🔒 Paid
- 2026-01-28 CytomX Therapeutics (CTMX): Scientific Deep Dive for Varseta-M and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.